Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.87 |
| ▸ | TP53 | P04637 | 1/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.87 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.87 |
| ▸ | TSHR | P16473 | 1/20 | 0.87 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.87 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.87 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.86 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059060 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL13567361 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL1060273 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Tetrahexylammonium SCHEMBL2521928 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL332137 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL1065743 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL4059099 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL1009645 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL158607 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL4685770 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906490-B2 | Multicolor mask | EASTMAN KODAK COMPANY (US) | 2014-12-09 | — | — | US | disclosed |
| US-8715894-B2 | Integrated color mask | EASTMAN KODAK COMPANY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8664673-B2 | Multicolored mask process for making display circuitry | EASTMAN KODAK COMPANY (US) | 2014-03-04 | — | — | US | disclosed |
| US-20120231239-A1 | INTEGRATED COLOR MASK | BANK OF AMERICA, N.A., AS AGENT | 2012-09-13 | — | — | US | disclosed |
| US-20120181554-A1 | MULTICOLORED MASK PROCESS FOR MAKING DISPLAY CIRCUITRY | BANK OF AMERICA, N.A., AS AGENT | 2012-07-19 | — | — | US | disclosed |
| US-8221964-B2 | Integrated color mask | EASTMAN KODAK COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-8173355-B2 | Gradient colored mask | EASTMAN KODAK COMPANY (US) | 2012-05-08 | — | — | US | disclosed |
| US-8153352-B2 | Multicolored mask process for making display circuitry | EASTMAN KODAK COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8129098-B2 | Colored mask combined with selective area deposition | EASTMAN KODAK COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-7947854-B2 | Phospholipase inhibitor; prevention or therapy of microbial infection; bactericides; fungicides; viricides; parasiticides; using quaternary or phosphonium group containing compounds | THE UNIVERSITY OF SYDNEY (AU) | 2011-05-24 | — | — | US | disclosed |
| US-20090130398-A1 | Gradient colored mask | LASER PACIFIC MEDIA CORPORATION | 2009-05-21 | — | — | US | disclosed |
| US-20090130600-A1 | Multicolored mask process for making display circuitry | QUALEX INC. | 2009-05-21 | — | — | US | disclosed |
| US-20080275003-A1 | Bis-Cationic Compounds and Use Thereof | THE UNIVERSITY OF SYDNEY (AU) | 2008-11-06 | — | — | US | disclosed |
| US-20080275003-A1 | Bis-Cationic Compounds and Use Thereof | THE UNIVERSITY OF SYDNEY (AU) | 2008-11-06 | — | — | US | disclosed |
| US-20080107878-A1 | Colored mask for forming transparent structures | EASTMAN KODAK COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20070269750-A1 | Colored masking for forming transparent structures | EASTMAN KODAK COMPANY | 2007-11-22 | — | — | US | disclosed |
| EP-1689698-A4 | BIS-CATIONIC COMPOUNDS AND USE THEREOF | UNIV SYDNEY (AU) | 2007-09-05 | — | — | EP | disclosed |
| US-7192680-B2 | Method of coating a multilayered element | EASTMAN KODAK COMPANY (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1689698-A1 | BIS-CATIONIC COMPOUNDS AND USE THEREOF | THE UNIVERSITY OF SYDNEY (AU) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005047230-A1 | BIS-CATIONIC COMPOUNDS AND USE THEREOF | THE UNIVERSITY OF SYDNEY (AU) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275003-A1 | Bis-Cationic Compounds and Use Thereof | PLCB1, PLCB3, PLA2G4B | SLC22A1 4131/4885ALDH1A1 4858/4885TP53 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.